• Users Online: 37
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 1  |  Issue : 3  |  Page : 192-197

DNA vaccine construct formation using Mycobacterium-specific gene Inh-A


1 The Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
2 Department of Biochemistry, The Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

Correspondence Address:
Dr. Mirza Imran Shahzad
Department of Biochemistry, The Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur
Pakistan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpdtsm.jpdtsm_63_22

Rights and Permissions

BACKGROUND: Tuberculosis (TB) remains a highly contagious disease and a leading cause of death worldwide. It is caused by Mycobacterium tuberculosis and Mycobacterium bovis. TB infection is still uncontrolled because of the unavailability of an effective vaccine, co-infection with HIV, lengthy treatment, and the emergence of resistant forms of M. tb like multi/extreme drug resistance strains. TB is mainly a disease of underdeveloped countries because of inadequate health facilities. The development of the new state of modern art vaccine-like DNA vaccine is a promising approach to control TB. The DNA vaccine can be used alone or in combination with Bacille Calmette Guerin (BCG). The objective of the current study is to develop an M. tb gene inh-A based DNA vaccine. METHODS: The immunodominant gene (Rv1484/INH-A) was amplified using sequence-specific primers. The amplified product was cloned into Topo 2.1 polymerase chain reaction vector, confirmed through restriction digestion and sequence analysis. Finally, subcloned into mammalian expression pVAX1 vector. RESULTS: The inh/A-pVAX1 construct was again confirmed through restriction digestion and sequence analysis. The rightly oriented constructs were selected, and these will be used for in Vivo DNA vaccine immunization studies. CONCLUSITONS: DNAvaccine can be used alone or in combination with BCG. DNA vaccines have enough potential to be used with TB treatment and reduce the treatment time in future.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed98    
    Printed2    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal